TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Hansa Biopharma AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
14,915
|
12,085
|
13,886 |
| Financial expenses |
16,294
|
9,510
|
4,371 |
| Earnings before taxes |
-80,596
|
-74,875
|
-54,813 |
| EBITDA |
-54,129
|
-70,176
|
-52,891 |
| Total assets |
179,567
|
91,748
|
151,632 |
| Current assets |
49,087
|
77,068
|
144,200 |
| Current liabilities |
22,072
|
28,928
|
23,787 |
| Equity capital |
58,717
|
-15,129
|
54,178 |
| - share capital |
5,904
|
4,960
|
4,945 |
| Employees (average) |
0
|
159
|
144 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
32.7%
|
-16.5%
|
35.7% |
| Turnover per employee |
76
|
96 | |
| Profit as a percentage of turnover |
-540.4%
|
-619.6%
|
-394.7% |
| Return on assets (ROA) |
-35.8%
|
-71.2%
|
-33.3% |
| Current ratio |
222.4%
|
266.4%
|
606.2% |
| Return on equity (ROE) |
-137.3%
|
494.9%
|
-101.2% |
| Change turnover | |||
| Change turnover % |
-13%
|
356% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
10%
|
24% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.